Cefic-lri Programme | European Chemical Industry Council

EMSG57-LAKIND: Endocrine disruptors and obesity, diabetes and heart disease: State of the science and biological plausibility

Principal Investigator

Dr. Judy LaKind
LaKind Associates, LLC
106 Oakdale Avenue
Catonsville, Maryland USA 21228
Tel: +1 410.788.8639

Fax: +1 410.788.8639

Collaborators

Michael Goodman, MD, Department of Epidemiology, Rollins School of Public Health, Emory University, USA, mgoodm2@emory.edu

Donald R. Mattison, MD, Risk Sciences International, USA, dmattison@risksciencesint.com

Description

This project builds on (i) the lessons learned from the recently completed work on methodologic issues affecting epidemiologic research on BPA and (ii) the findings of the project (conducted under Cefic-LRI EMSG54) related to the importance of harmonization of epidemiologic methods for weight-of-evidence assessment. This relevant experience will be used to examine in detail the studies of endocrine disruptors in relation to obesity, diabetes and heart disease.

This project addresses the RfP pbjectives in three phases that will bring a fresh perspective to the complex and important issue of exogenous endocrine disruptors as determinants of human health outcomes:

Phase 1: Critical literature review and meta-analysis with 1 or 2 exemplar chemicals: Assessment of consistency across results and sufficiency of evidence for a given chemical.
Phase 2: Critical examination of methodologic issues affecting epidemiologic research on endocrine-active environmental chemicals: Assessment of the relation between study methods and reported findings.
Phase 3: Evaluation of biological plausibility: Assessment of epidemiological and clinical trial findings with chemical and pharmacologic mechanisms of action using exemplar drugs.

Related Publications

Publications:

Judy S. LaKind, Michael Goodman & Donald R. Mattison. Bisphenol A and indicators of obesity, glucose metabolism/type 2 diabetes and cardiovascular disease: A systematic review of epidemiologic research. Crit Rev Toxicol. 2014 Feb;44(2):121-50.

Michael Goodman, Judy S. LaKind & Donald R. Mattison. Do phthalates act as obesogens in humans? A systematic review of the epidemiological literature. Crit Rev Toxicol. 2014 Feb;44(2):151-75.

Donald R. Mattison, Nataliya Karyakina, Michael Goodman & Judy S. LaKind (2014). Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: A review of the data and identification of knowledge gaps.  Crit Rev Toxicol. 2014 Sep;44(8):696-724.

Click here for further information

Timeline: January 2013 > July 2013

LRI funding: $ 150 000

Cefic-Lri Programme Responsible Care

© Copyright 2017 Cefic | European Chemical Industry Council. All rights reserved | Terms and Conditions of Use